source
- Immunocore reports early data showing 70% two-year survival with brenetafusp/Kimmtrak combo in uveal melanomaImmunocore presented early clinical data on its bispecific T-cell engager combination brenetafusp and Kimmtrak in patients with uveal melanoma. The analysis, based on a subset of patients, indicat…
- Moderna posts first profit in two years, driven by Covid-19 vaccine sales, as it refocuses on cancer vaccinesModerna reported a modest profit for the quarter, marking its first earnings surplus in two years. The turnaround was driven primarily by continued sales of its international Covid-19 vaccine portf…Endpoints · 3d agoEarningsPositive